Company Overview

Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical company headquartered in Japan, operating primarily in the pharmaceutical and biotechnology industries. The company focuses on the discovery, development, manufacturing, and commercialization of prescription medicines, with an emphasis on innovative therapies and specialty care. Its core therapeutic areas include Gastroenterology, Oncology, Rare Diseases, Neuroscience, and Plasma-Derived Therapies, which together represent the majority of its revenue base.

Founded in 1781 as a traditional Japanese medicine wholesaler, Takeda is one of the oldest pharmaceutical companies in the world. Over more than two centuries, it evolved from a domestic medicine supplier into a multinational biopharmaceutical company through sustained investment in research and development and a series of strategic international acquisitions. A pivotal transformation occurred with the acquisition of Shire plc in 2019, significantly expanding Takeda’s global footprint and rare disease portfolio, and repositioning the company as a leading global specialty biopharmaceutical firm.

Business Operations

Takeda organizes its operations around key business areas aligned to its therapeutic focus, primarily Gastrointestinal and Inflammation, Oncology, Rare Diseases, Neuroscience, and Plasma-Derived Therapies. Revenue is generated through the sale of branded prescription medicines, biologics, and plasma-derived products, supported by an integrated global manufacturing and supply chain network. The company maintains extensive research and development capabilities, with clinical development programs spanning early-stage research through late-stage clinical trials.

Operations are geographically diversified, with significant activities in Japan, North America, and Europe, complemented by emerging market operations. Takeda controls a broad portfolio of proprietary compounds, biologics manufacturing facilities, and plasma collection centers, largely through its subsidiary Takeda Pharmaceutical International AG and plasma-focused unit Takeda’s Plasma-Derived Therapies Business (formerly associated with Shire’s Baxalta assets). The company also maintains collaborations with academic institutions and biotechnology partners to advance innovation and clinical development.

Strategic Position & Investments

Takeda’s strategy centers on delivering long-term growth through innovation in its core therapeutic areas while maintaining financial discipline and operational efficiency. The company prioritizes investment in late-stage and commercial assets, life-cycle management of key products, and targeted research platforms such as biologics and cell therapies. Post-Shire acquisition, Takeda has focused on debt reduction, portfolio optimization, and divestment of non-core assets to strengthen its balance sheet.

Major investments have included continued integration and expansion of Shire plc’s rare disease and plasma-derived therapy franchises, as well as selective acquisitions and licensing agreements to enhance its oncology and gastrointestinal pipelines. Takeda also invests in emerging technologies such as gene therapy, digital health applications supporting clinical trials, and advanced biologics manufacturing, while maintaining notable subsidiaries including Takeda Development Center Americas, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Geographic Footprint

Takeda operates in more than 80 countries, with a strong presence across Asia-Pacific, North America, Europe, and Latin America. Its global headquarters are located in Tokyo, Japan, while regional hubs support commercial, research, and manufacturing activities in the United States, Switzerland, and Singapore. The company’s international structure enables localized market access strategies while leveraging centralized research and development oversight.

Manufacturing and plasma collection facilities are distributed globally, supporting both regional supply needs and international distribution. Takeda’s influence extends across developed and emerging markets, with significant investment in the United States and Europe for research and commercialization, and expanding operations in China, Brazil, and other growth markets to increase patient access to its therapies.

Leadership & Governance

Takeda is led by an executive team that emphasizes patient-centric values, long-term value creation, and ethical governance. The company’s leadership philosophy is grounded in its corporate credo, which prioritizes patients, people, and the planet while balancing sustainable growth and innovation. Governance practices align with international standards, supported by a board with global pharmaceutical and financial expertise.

Key executives include:

• Christophe Weber – President and Chief Executive Officer
• Julie Kim – President, U.S. Business Unit and U.S. Country Head
• Ramona Sequeira – President, Global Portfolio Division
• Roger Dansey – Chief Medical Officer
• Iain Boucher – Chief Financial Officer
• Christophe Raibaut – Chief Data and Technology Officer